The treatment was administered by intramuscular injection followed by electroporation in combination with anti-PD-L1 and anti-CTLA-4 ICB therapy, manifesting a potent antitumor response that increased the survival of mice in different tumor models [141]. This evidence concerns the gene CTLA4 and neoplasm.